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Abstract
Transparency in health economic decision modelling is important for engendering confidence in the models and in the 
reliability of model-based cost-effectiveness analyses. The Mount Hood Diabetes Challenge Network has taken a lead in 
promoting transparency through validation with biennial conferences in which diabetes modelling groups meet to compare 
simulated outcomes of pre-specified scenarios often based on the results of pivotal clinical trials. Model registration is a 
potential method for promoting transparency, while also reducing the duplication of effort. An important network initia-
tive is the ongoing construction of a diabetes model registry (https ://www.mthoo ddiab etesc halle nge.com). Following the 
2012 International Society for Pharmacoeconomics and Outcomes Research and the Society of Medical Decision Making 
(ISPOR-SMDM) guidelines, we recommend that modelling groups provide technical and non-technical documentation 
sufficient to enable model reproduction, but not necessarily provide the model code. We also request that modelling groups 
upload documentation on the methods and outcomes of validation efforts, and run reference case simulations so that model 
outcomes can be compared. In this paper, we discuss conflicting definitions of transparency in health economic modelling, 
and describe the ongoing development of a registry of economic models for diabetes through the Mount Hood Diabetes 
Challenge Network, its objectives and potential further developments, and highlight the challenges in its construction and 
maintenance. The support of key stakeholders such as decision-making bodies and journals is key to ensuring the success 
of this and other registries. In the absence of public funding, the development of a network of modellers is of huge value in 
enhancing transparency, whether through registries or other means.
 * Philip Clarke 
 philip.clarke@ndph.ox.ac.uk
Extended author information available on the last page of the article
Key Points 
Improving the transparency of health economic decision 
modelling will enhance the reliability of model-based 
cost-effectiveness analyses.
The Mount Hood Diabetes Challenge Network has estab-
lished a registry of health economic models of diabetes 
containing structured information about each model and 
outcomes for reference simulations.
The development of modelling networks is of huge value 
in promoting transparency in economic modelling.
The support of stakeholders including decision-making 
bodies and journals and public funding is key to ensuring 
the success of model registries.
1 Introduction
There is growing recognition that a lack of transparency 
in medical research may be a barrier to good decision 
making in health care [1–3]. This may result directly, for 
instance, from publication bias (i.e. the non-reporting of 
negative results), which can bias the known evidence base 
that informs decisions. In addition, poor transparency may 
cause stakeholders to have less confidence in the evidence 
generated by medical research, for example, because of 
misplaced concerns about publication bias, an inability to 
interpret complex evidence or to reproduce the evidence, or 
the absence of evidence on the validity of research methods. 
Calls for increased transparency in medical research have 
inspired many responses, including the AllTrials movement 
[4], which seeks to ensure that all clinical trials are prospec-
tively registered and reported, and the open data movement 
[5], which maintains that providing data and analysis pro-
gramming code permits greater scrutiny and promotes the 
replication of analyses and results.
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Cost-effectiveness analysis, which formally compares the 
relative costs and relative benefits of two or more treatment 
options, is an important component of resource allocation in 
health care. Many governmental and private bodies worldwide 
make reimbursement decisions and develop clinical and pub-
lic health guidelines using such evidence [6]. Clinical trials 
can provide valuable data on the costs and effects of alter-
native technologies. For chronic and progressive diseases, 
trial durations are routinely too short to capture all health and 
economic consequences resulting from an intervention. Addi-
tionally, they rarely contain all outcomes and all comparators 
needed for economic evaluation and, in many cases, the analy-
sis must be translated to a different setting (e.g. with different 
populations, treatment patterns, and/or unit costs) [7]. Deci-
sion analytic models, formal mathematical frameworks that 
synthesise clinical and economic data from a range of sources 
and extrapolate from these data over time and/or setting, are 
therefore routinely used to generate estimates of lifetime cost-
effectiveness, and some health technology assessment bod-
ies, for example, the National Institute of Health and Care 
Excellence (NICE) in the UK, require modelling for many 
technology appraisals [8].
Health economic decision models are often complex, 
particularly for chronic and progressive diseases like diabe-
tes, and modellers are required to make numerous decisions 
during model development including in the structure of the 
model and in the selection and processing of underlying 
clinical and economic data. Each decision, individually or 
collectively, can affect the resulting estimate of cost-effec-
tiveness [9]. The importance of transparently reporting mod-
elling efforts is now widely recognised, and some guidelines 
have been developed to support it [10]. Nevertheless, the 
Second Panel on Cost-Effectiveness in Health and Medi-
cine identified increasing model transparency as a key area 
of future research in order to enhance the reliability and 
validity of health economics research, and ultimately the 
use of such research in decision making [11]. The purpose 
of this paper is to describe the role of the Mount Hood Dia-
betes Challenge Network in promoting model transparency 
through a model registry including the results of standard-
ised validation exercises [12–15]. We discuss the opportu-
nities and challenges associated with the development and 
maintenance of a registry of economic models for diabetes.
2  What is Model Transparency and How Can 
it be Promoted?
While there is almost universal agreement that enhanc-
ing transparency in health economic decision modelling 
is important [11, 16], there are competing definitions of 
transparency and disagreements about how it should best 
be operationalised; for example, whether transparency 
necessitates the sharing of model code [17]. A report by 
the International Society for Pharmacoeconomics and Out-
comes Research and the Society of Medical Decision Mak-
ing (ISPOR-SMDM) provides an informative and pragmatic 
guide to enhance the understanding of model transparency 
and validation [16]. Importantly, ISPOR-SMDM recognise 
that transparency is not an end in itself, but rather a means 
to enhancing model credibility: a transparent model does not 
guarantee validity, while a valid model may not be transpar-
ent [16, 18].
According to the authors of this report, transparency 
involves the provision of sufficient information to enable 
readers, whether they are specialists or non-specialists, to 
understand a model’s accuracy, limitations, and potential 
applications [16]. This requires both non-technical and tech-
nical documentation. Non-technical documentation should 
provide details about the model structure and its potential 
applications, though not at the level of detail required to 
support replication. Technical documentation should provide 
substantial details about model structure, equations and data 
input such that model reproduction is, in theory, possible, 
and can, at the modeller’s discretion, include access to the 
model code itself.
Demonstrating the validity of a model increases the 
confidence in its use for health care decision making. The 
ISPOR-SMDM report defines validation as a set of meth-
ods for judging a model’s accuracy in making relevant pre-
dictions [16]. Others have contended that a focus on accu-
racy is misplaced in health economic decision modelling 
given the inherent uncertainties involved in such work, and 
instead recommend a focus on the extent to which a model 
is a proper and sufficient representation of the system it is 
intended to represent [19]. Validation encompasses many 
methods, including face validity, internal validity, cross-
validity, external validity, and predictive validity. Checklists 
such as the AdViSHE validation-assessment tool provide 
guidance on reporting validation exercises, with the aim of 
promoting transparency in assessing model validity for the 
benefit of decision makers and other model users [20].
There is also value in subjecting all models used for simi-
lar applications (e.g. in a particular disease area) to a com-
mon set of simulation scenarios. This could involve replicat-
ing exercises such as replicating the results of clinical trials 
[14] as well as running ‘reference case simulations’ involv-
ing a pre-defined simulation for a representative patient or 
population. Comparing models against observed data (i.e. 
external validation) and against each other (i.e. cross-valida-
tion) provides valuable information about model validity and 
promotes transparency. Reporting the results of reference 
simulations would also provide information about changes to 
individual models over time. It is also important that infor-
mation on methods and outcomes are well documented and 
ideally presented in a standardised structure [12–15, 20–22]. 
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This would help also limit the selective reporting of vali-
dation studies since modelling groups would have to pre-
commit to undertaking validations prior to knowledge of 
the results.
The provision of model code is often considered an inte-
gral part of promoting transparency [17]. Researchers, how-
ever, may be concerned that the provision of code could 
result in others using their model without appropriate attri-
bution or amending the model in a way that impairs its valid-
ity. The ISPOR-SMDM guidelines on model transparency 
and validation suggest, however, that model code should be 
provided at the discretion of the modellers in order to pro-
tect intellectual property [16]. Moreover, while model code 
entails a comprehensive account of the model, it is often 
highly complex (particularly for chronic conditions like dia-
betes), rendering it extremely difficult for ordinary users to 
understand and use, and may result in misuse of the model 
(whether intentional or not). There are many alternatives to 
providing code, which may be more useful. First, structured, 
technical and non-technical documentation can, as noted 
above, provide useful and easily comprehensible informa-
tion about model data and structure. Second, components 
of models can be made available, like the risk equations in 
the United Kingdom Prospective Diabetes Study (UKPDS) 
Outcomes Model [23], which is currently used in many other 
diabetes models [15]. Third, user interfaces can be created 
to allow users to vary values of parameters, and potentially 
structural assumptions, and to derive outcomes. An open-
access example is the Study of Heart and Renal Protection 
Chronic Kidney Disease–Cardiovascular Disease (SHARP 
CKD-CVD) model [24], which is available at http://dismo 
d.ndph.ox.ac.uk/kidne ymode l/app/.
Modellers can follow the ISPOR-SMDM and AdViSHE 
recommendations by publishing technical and non-technical 
documents and reporting validation efforts on publicly avail-
able websites, in scientific journals, or in other venues. The 
quality of reporting of economic evaluations is, however, 
known to vary widely [10]. Moreover, even if such infor-
mation was routinely provided, individuals or organisations 
that required access to it would nevertheless face barriers 
in identifying the appropriate information and ensuring it 
is current, complete, and valid for the model application at 
hand. As a consequence, the status quo can lead to the dupli-
cation of effort, whether in the construction of new models 
or in assessing the validity of existing models [20, 25]. In 
addition, the lack of consistent (and consistently reported) 
validation exercises would limit the confidence that a model 
user has in model results.
Model registration has been proposed as a solution to 
these and other problems [25–27]. Sampson and Wrightson 
[25] argued that a registry combined with a linked database 
of model-based economic evaluations could help overcome 
publication bias (though the feasibility of pre-registration of 
all analysis plans in the context of model-based economic 
evaluations is less than in clinical trials), and may promote 
collaborative validation exercises. Model registration, so 
envisaged, provides a single repository or linked reposito-
ries for models and their applications, potentially containing 
relevant technical and non-technical documentation, ideally 
in a standardised format so as to ensure consistent and com-
plete representation of all models. It can also act as a reposi-
tory for validation tests, ensuring the consistent reporting of 
validation methods and outcomes [15, 20]. Another benefit 
of a registry would be to facilitate collaboration between 
researchers, and engagement with other stakeholders (such 
as reimbursement bodies, providers, and industry).
3  The Mount Hood Diabetes Challenge 
Network
In 2000, two diabetes modelling groups met at Mount 
Hood in Oregon, USA, and jointly designed and ran several 
simulations with their models [12]. The predictions of the 
cumulative incidence of various clinical events were then 
compared to provide insights into model reliability. This 
meeting inspired the Mount Hood Diabetes Challenge Net-
work, which has assembled on a further eight occasions, 
and biennially since 2010, with an increasing number of 
modelling groups and participants present (Tables 1, 2). 
The most recent meeting in October 2018, at the German 
Diabetes Centre (Deutsches Diabetes-Zentrum, Düsseldorf, 
Germany), involved 13 modelling teams and 70 participants. 
Modelling teams participating in the challenges are 
provided with a series of instructions typically describing 
either clinical trials that have been undertaken in diabetes 
or reference simulations and are asked to submit model 
results prior to the conference in a pre-circulated template, 
which requires modelling teams to specify any additional 
assumptions they were required to make. Each meeting 
has a somewhat different focus, e.g. on subgroup results, 
health-related quality of life, the handling of uncertainty, 
or reproducibility of results. For example, for challenge #2 
of the 2018 meeting, modelling teams were requested to 
run simulations to investigate the impact of utility values 
and stipulated changes in common diabetes risk factors 
(glycated haemoglobin [HbA1c], systolic blood pressure, 
low-density lipoprotein cholesterol, and body mass index) 
on life expectancy and quality-adjusted life-years in hypo-
thetical patients with pre-specified characteristics. As part of 
the 2016 Mount Hood Diabetes Challenge Network meeting, 
modelling groups defined a minimum set of reporting stand-
ards for describing and reporting model inputs in diabetes 
health economic studies [15]; these incorporated informa-
tion on the simulation cohort, the treatment interventions, 
costs, health state utilities, and other model characteristics 
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that may have a substantive impact on model transparency 
(Table 3). A comprehensive record of all Mount Hood Dia-
betes Network challenges is provided on the network’s web-
site (https ://www.mthoo ddiab etesc halle nge.com/archi ve).
At the meetings, the outcomes from participating mod-
els are compared to each other (i.e. cross-validation) and 
to observed data if applicable (i.e. internal and/or external 
validation), and the proceedings are often published in a 
peer-reviewed journal [12–15]. The Mount Hood Diabetes 
Challenge Network has spawned similar exercises in other 
disease areas including chronic obstructive pulmonary dis-
ease [22]. Other initiatives also exist, for instance, the Can-
cer Intervention and Surveillance Modelling Network (CIS-
NET) funded with multiple grants by the National Cancer 
Institute in the United States [21].
4  Plans for a Mount Hood Diabetes 
Challenge Network Model Registry
There are several registries pertaining to specific com-
ponents of health economics [25], including published 
cost-effectiveness analyses [28], mapping algorithms (e.g. 
mapping from disease-specific quality-of-life measures to 
EQ-5D) [29], resource use measurement [30], and health 
state utility values [31]. There is, however, no comprehen-
sive registry for health economic decision models or model 
applications, and only rare examples of disease-specific 
ones, e.g. the CISNET registry of cancer models (https ://
resou rces.cisne t.cance r.gov/regis try) [21].
In an attempt to extend the efforts of the Mount Hood 
Diabetes Challenge Network in promoting transparency 
in diabetes modelling, and in response to recent calls for 
a registry of economic models [25, 27], we established a 
registry of models in the area of diabetes. The Mount Hood 
Diabetes Challenge Network is well-positioned to push this 
agenda given its large and established network of researchers 
in diabetes modelling from around the world representing 
both academia and industry. Furthermore, diabetes is an area 
where such an exercise may be most valuable, as most mod-
els are used and updated repeatedly for many different appli-
cations. An initial model registry is located on the Mount 
Hood Diabetes Challenge Network website: https ://www.
mthoo ddiab etesc halle nge.com/regis try. Currently, the reg-
istry is limited to non-technical descriptions of each model, 
with links to technical descriptions and published reports. 
The Mount Hood Diabetes Challenge Network collaborators 
are currently in the process of deciding on a structured form 
for the technical and non-technical descriptions of contrib-
uting models. Modelling groups should provide sufficient 
information to allow evaluation of a model’s validity and, 
in theory, the reproduction of the model. The registry could 
also serve as a repository for model programming code, 
should modelling groups elect to provide it.
An important component of the proposed registry is the 
inclusion of validation exercises. This is expected to take 
two forms. First, modelling groups would be expected to 
report the methods and outcomes from their own validation 
efforts in a structured form, for instance, using the AdViSHE 
validation-assessment tool [20]. Second, all model versions 
would be encouraged to run and provide results for several 
pre-defined scenarios (i.e., reference simulations), and report 
their methods (Table 3) and results in a structured format. 
The final set of reference case simulations will be decided 
by consultation with the various participating modelling 
groups, and would be subject to changes or supplementation 
over time. The reference case simulations should reflect dif-
ferent aspects of the models and different patient characteris-
tics, and may even provide something akin to outcome tables 
which simulate outcomes such as life expectancy over a wide 
range of possible risk factors and levels of risk factors [32].
Table 1  Information on 
previous and forthcoming 









1 2000 Mount Hood, Oregon, United States 2 6
2 2002 San Francisco, United States 6 62
3 2003 Oxford, United Kingdom 6 52
4 2004 Basel, Switzerland 8 ~ 50
5 2010 Lund, Sweden 8 77
6 2012 Baltimore, United States 8 79
7 2014 Palo Alto, United States 11 77
8 2016 St Gallen, Switzerland 10 57
9 2018 Dusseldorf, Germany 13 70
10 2020 Chicago, United States –
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4.1  Challenges to Constructing and Maintaining 
a Registry
Most diabetes models are designed for multiple applica-
tions, and so many undergo continual or periodic develop-
ment over time and must often be adapted to evaluate par-
ticular interventions. One way to document model changes 
would be to require the modellers to register any substantive 
changes to model structure that produce variations to the 
outcomes reported in the reference case. This would place 
the responsibility on modellers to periodically update entries 
in the register (just as it is important for trials to register 
amendments to protocols [33]). Like computer software, 
models would ideally be provided in defined versions and 
variants; this would strengthen the ability to reproduce pre-
viously computed or published model results.
Including reference simulations places an onus on the 
modellers. Ideally, a large number of conceptually varied 
reference simulations would be defined to reflect the com-
plexity of modelling in diabetes, the importance of various 
Table 2  Participation of models 
at Mount Hood Challenge 
meetings
Model Year of meeting




CDC-RTI Diabetes Cost-effectiveness 
Model










IQVIA CORE Diabetes Model
IQVIA CORE Hypertension Model
MDM Treatment Transitions Model
Medical Decision Making Treatment 
Transitions Model
MICADO
Michigan Model for Diabetes
MMUs Diabetes Model
Ontario Diabetes Economic Model
PRIME Diabetes Model










More information on many of these models can be obtained from the register of diabetes models, listed 
on www.mthoo ddiab etesc halle nge.com
Shaded cells indicate that the corresponding model participated in the challenges
SHARP CKD-CVD Study of Heart and Renal Protection Chronic Kidney Disease–Cardiovascular Dis-
ease, UKPDS United Kingdom Prospective Diabetes Study
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different parameters and assumptions for cost-effectiveness, 
and account for the fact that some models will perform well 
in some simulations but not in others. The number of simula-
tions should not overburden the contributors or complicate 
review by independent researchers or organisations, which 
would risk poor compliance and underutilisation. There 
are also challenges inherent in the definition of any single 
reference simulation: standardisation must be sufficient to 
enable comparison, while allowing for each model to retain 
its defining characteristics.
However, a big challenge is overcoming inertia and the 
absence of general infrastructure to enable health economic 
decision models to be registered. The Mount Hood Diabetes 
Challenge Network is at an advantage here because of its 
long-established network of modellers in diabetes and a web-
site which can host a registry for diabetes simulation models. 
However, as participation is currently voluntary, such a registry 
will only attract a subset of models. It is therefore important to 
engage key stakeholders including both medical journal editors 
and decision-making bodies. Here we can draw on the experi-
ence of clinical trial registries which have been assisted with 
public funding for infrastructure (e.g. ClinicalTrials.gov was set 
up by the Food and Drug Administration in the US [33]) and 
by journal editors mandating registration of clinical trials [34]. 
It is hard to envision how a comprehensive register of health 
economics models can be achieved without similar support.
Table 3  Diabetes modelling input checklist. Reproduced from Palmer et al. (2018) [15]
BMI body mass index, HbA1c glycated haemoglobin
Model input Checkbox Comments (e.g. 














 Treatment algorithm for HbA1c evolution over time
 Treatment algorithm for other conditions (e.g. hypertension, dyslipidaemia, and excess weight)
 Treatment initial effects on baseline biomarkers
 Rules for treatment intensification (e.g. the cut-off HbA1c level to switch the treatment, the type of new treat-
ment, and whether the rescue treatment is an addition or substitution to the standard treatment)
 Long-term effects, adverse effects, treatment adherence and persistence, and residual effects after the discon-
tinuation of the treatment
 Trajectory of biomarkers, BMI, smoking, and any other factors that are affected by treatment
Cost
 Differentiated by acute event in the first year and subsequent years
 Cost of intervention and other costs (e.g. managing complications, adverse events, and diagnostics)
 Please report unit prices and resource use separately and give information on discount rates applied
Health state utilities
 Operational mechanics of the assignment of utility values (i.e. utility- or disutility-oriented)
 Management of multihealth conditions
General model characteristics
 Choice of mortality table and any specific event-related mortality
 Choice and source of risk equations
 If microsimulation, number of Monte-Carlo simulations conducted and justification
 Components of model uncertainty being simulated (e.g. risk equations, risk factor trajectories, costs, and 
treatment effect); number of simulations and justification
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5  Conclusions
The complexity and scale of many health economic decision 
models necessitates a move beyond the usual methods of 
peer review in order to enhance transparency. The develop-
ment of a modelling network is a way to promote transpar-
ency by bringing together health economists and computer 
simulation modellers and engaging in an ongoing process 
of review. The Mount Hood Diabetes Challenge Network 
provides a working example of how to develop and maintain 
a health-economics modelling community. For example, past 
meetings of the network have used challenges to promote 
external model validation of a large number of diabetes mod-
els [14] and an examination of transparency in reporting of 
simulations used in economic evaluations of therapies for 
diabetes [15]. A network not only promotes these aspects 
of transparency, but also provides a regular forum where 
models can be reviewed by peers. It can also facilitate the 
development of bespoke modelling and reporting guidelines 
[15] which complement more general modelling guidelines 
by taking into account specific modelling challenges in a 
particular disease area like diabetes.
Another reason for developing networks is that it is a way 
to maintain model registries, containing systematic technical 
and non-technical information about models. We have argued 
that such a registry could be enhanced by reporting the results 
from several reference case simulations, as this helps improve 
transparency and confidence in the use of models for deci-
sion making, and ultimately, in the decisions themselves. The 
Mount Hood Diabetes Challenge Network has established 
one of the first registries to provide information on a wide 
range of health economic decision models in standard format. 
Although this is just the first step, it is nevertheless a posi-
tive one on a long road to developing a general register of 
health economic models. The support of major stakeholders 
such as decision-making bodies and journals, for example, by 
encouraging or even mandating model registration, and pub-
lic funding is key to furthering this venture. In the absence 
of funding, the establishment of modelling networks like the 
Mount Hood Diabetes Challenge Network is essential.
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